Engineered immune cells take aim at Hard-to-Treat autoimmune diseases
Disease control
Recruiting now
This early-stage trial tests an experimental cell therapy called NEUK203-215 in adults aged 18-65 with severe autoimmune diseases like lupus or scleroderma that have not responded to other treatments. The therapy uses immune cells from a healthy donor, engineered to target and at…
Phase: EARLY_PHASE1 • Sponsor: Neukio Biotherapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC